Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company?s ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson?s disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC; Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; F. Hoffmann?La Roche Ltd; Hoffmann-La Roche Inc.; and Open Monoclonal Technology, Inc. Sangamo BioSciences was founded in 1995 and is based in Richmond, California.